PolyPeptide SA
485.0 FTEThe score of PolyPeptide shows with a free account.
See the score- Summary? / 5
- Solvency
- Liquidity
- Interest coverage
- Profitability
- Leverage
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +58 % Equity +6 % Total assets +58 % Headcount (avg FTE) +23 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →PolyPeptide's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €156.1m | ||||
| Net result | €7.24m | ||||
| Equity | €103.8m | ||||
| Cash | 87,135 € | ||||
| EBITDA | €24.7m | ||||
| Total assets | €331.7m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 11 Jun 2026
- Year ended 31 Dec 2024filed on 03 Jun 2025
- Year ended 31 Dec 2023filed on 28 May 2024
- Year ended 31 Dec 2022filed on 30 May 2023
- Year ended 31 Dec 2021filed on 09 Jun 2022
PolyPeptide's financial analysis
- Solvency31.3%sector median: 38.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of PolyPeptide
PolyPeptide's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0879.346.768
- VAT number
- BE0879346768
- Peppol
- Registered · 0208:0879346768 · as of 18 Oct 2026
- Legal form
- SA
- Incorporated
- 14 Feb 2006
- Registered office
- 1420 Braine-l'Alleud
- Size
- Large · 485.0 FTE
- Latest accounts
- 2025 · filed on 11 Jun 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
PolyPeptide (SA) has been based in Braine-l'Alleud since 2006, active in: manufacture of basic pharmaceutical products. For 2025, it reports revenue of €156.1m, a net profit of €7.24m and equity of €103.8m. With 485.0 full-time equivalents, it is a large enterprise by headcount. Its solvency stands at 31.3%, below the median of its sector (38.7%).
Companies similar to PolyPeptide
Companies in the same business, of comparable size and area, outside its group.
- Ajinomoto Omnichem Manufacture of basic pharmaceutical products Wetteren · balance sheet €476.3m
- Novartis Manufacturing Manufacture of pharmaceutical preparations Puurs-Sint-Amands · balance sheet €285.2m
- Telix Innovations Manufacture of basic pharmaceutical products Herstal · balance sheet €473.4m
- Pfizer Manufacture of pharmaceutical preparations Ixelles · balance sheet €377.4m
- Evonik Oxeno Antwerpen NV Manufacture of other organic basic chemicals Antwerp · balance sheet €142.2m
- PHOENIX Pharma Belgium Manufacture of pharmaceutical preparations Woluwe-Saint-Lambert · balance sheet €235.4m
- Novo Nordisk Production Belgium SA Manufacture of pharmaceutical preparations Brussels · balance sheet €153.5m
- SERB Wholesale of pharmaceutical and medical goods Ixelles · balance sheet €159.3m
Frequently asked questions about PolyPeptide
What is the revenue of PolyPeptide?
According to the 2025 annual accounts filed with the NBB, the revenue of PolyPeptide amounts to 156,109,657 €.
What is the VAT number of PolyPeptide?
In Belgium, the VAT number is the company number prefixed with BE: BE0879346768 for PolyPeptide, if the company is VAT-registered. Its company number (CBE) is 0879.346.768.
Where is the registered office of PolyPeptide?
According to the CBE register, the registered office of PolyPeptide is in 1420 Braine-l'Alleud.
What is the equity of PolyPeptide?
At the close of the 2025 financial year, the equity of PolyPeptide amounts to 103,798,985 €, a solvency of 31.3% of total assets.
How many people work at PolyPeptide?
485.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages PolyPeptide?
The register lists 2 active mandates at PolyPeptide. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of PolyPeptide
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →